Which pharmaceutical company produces ibrutinib/ibrutinib?

Ibrutinib/Ibrutinib (Ibrutinib) is the first Bruton's tyrosine kinase (BTK) inhibitor to be widely used in clinical practice. It has triggered major changes in the field of hematological cancer treatment since its launch. Many patients and the medical community are very concerned about its research and development background and pharmaceutical company information. In fact, ibrutinib was first developed by Pharmacyclics in the United States, and then established a cooperative relationship with Janssen, a subsidiary of the world-renowned pharmaceutical company Johnson & Johnson. Ultimately, ibrutinib was jointly developed and produced by Pharmacyclics and Janssen and marketed globally under the trade name "Imbruvica".

In the European and American markets, ibrutinib was first approved by the US FDA in 2013 and became a landmark drug for the treatment of mantle cell lymphoma (MCL). Since then, its indications have gradually expanded to include chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom's macroglobulinemia (WM), and chronic graft-versus-host disease (cGVHD). As a representative of BTK inhibitors, ibrutinib blocks B cell signaling pathways by irreversibly binding to BTK proteins, thereby inhibiting the survival and proliferation of malignant B cells and improving patient prognosis.

The production and promotion model of ibrutinib is representative in the pharmaceutical industry. Pharmacyclics was responsible for R&D in the early stage and completed the pre-clinical and early clinical verification of the drug with its in-depth research on BTK targets; while Janssen Pharmaceuticals relied on its advantages in global drug registration, marketing and production chain to quickly promote ibrutinib to the international market. In 2015, AbbVie acquired Pharmacyclics for billions of dollars, thereby gaining global commercial interests in ibrutinib. Since then, the production and distribution of ibrutinib has been primarily shared by AbbVie and Janssen.

Reference materials:https://www.imbruvica.com/